Gregory M Hermann1, Austin J Iovoli2, Alexis J Platek2, Chong Wang3, Austin Miller3, Kristopher Attwood3, Daniel J Bourgeois1,4, Anurag K Singh1. 1. Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York. 2. Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York. 3. Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, New York. 4. Radiation Oncology, Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana.
Abstract
BACKGROUND: The objective of the current study was to compare the safety and efficacy between 2 analgesic regimens for patients with head and neck cancer (HNC) undergoing definitive chemoradiation (CRT). METHODS: The current study was a prospective, single-institution, 2-arm, randomized pilot study. Patients with American Joint Committee on Cancer seventh edition stage II to stage IV squamous cell carcinoma of the head and neck who were undergoing CRT were randomized to either arm 1, which entailed high-dose gabapentin (2700 mg daily) with the institutional standard of care (hydrocodone and/or acetaminophen progressing to fentanyl as needed), or arm 2, which comprised low-dose gabapentin (900 mg daily) with methadone. The primary endpoints were safety and toxicity. Secondary endpoints were pain, opioid requirement, and quality of life (QOL). Differences between the treatment arms at multiple time points were compared using a generalized linear mixed regression model with Sidak correction. RESULTS: A total of 60 patients (31 in arm 1 and 29 in arm 2) were enrolled from April 2015 to August 2017. There was no difference between the treatment arms with regard to adverse events or serious adverse events. Pain was not found to be different between the treatment arms. More patients in arm 1 did not require an opioid during treatment (42% vs 7%; P = .002). Patients in arm 2 experienced significantly better QOL outcomes across multiple domains, including overall health (P = .05), physical functioning (P = .04), role functioning (P = .01), and social functioning (P = .01). CONCLUSIONS: High-dose prophylactic gabapentin increased the percentage of patients who required no opioid during treatment. Methadone may improve QOL compared with a regimen of short-acting opioids and fentanyl. However, pain was found to significantly worsen throughout treatment regardless of treatment arm, necessitating further studies to identify a more optimal regimen.
BACKGROUND: The objective of the current study was to compare the safety and efficacy between 2 analgesic regimens for patients with head and neck cancer (HNC) undergoing definitive chemoradiation (CRT). METHODS: The current study was a prospective, single-institution, 2-arm, randomized pilot study. Patients with American Joint Committee on Cancer seventh edition stage II to stage IV squamous cell carcinoma of the head and neck who were undergoing CRT were randomized to either arm 1, which entailed high-dose gabapentin (2700 mg daily) with the institutional standard of care (hydrocodone and/or acetaminophen progressing to fentanyl as needed), or arm 2, which comprised low-dose gabapentin (900 mg daily) with methadone. The primary endpoints were safety and toxicity. Secondary endpoints were pain, opioid requirement, and quality of life (QOL). Differences between the treatment arms at multiple time points were compared using a generalized linear mixed regression model with Sidak correction. RESULTS: A total of 60 patients (31 in arm 1 and 29 in arm 2) were enrolled from April 2015 to August 2017. There was no difference between the treatment arms with regard to adverse events or serious adverse events. Pain was not found to be different between the treatment arms. More patients in arm 1 did not require an opioid during treatment (42% vs 7%; P = .002). Patients in arm 2 experienced significantly better QOL outcomes across multiple domains, including overall health (P = .05), physical functioning (P = .04), role functioning (P = .01), and social functioning (P = .01). CONCLUSIONS: High-dose prophylactic gabapentin increased the percentage of patients who required no opioid during treatment. Methadone may improve QOL compared with a regimen of short-acting opioids and fentanyl. However, pain was found to significantly worsen throughout treatment regardless of treatment arm, necessitating further studies to identify a more optimal regimen.
Keywords:
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; Oral Mucositis Weekly Questionnaire adapted for head and neck cancer (OMWQ-HN); oral mucositis; patient-report outcomes; quality of life; version 3.0 (EORTC QLQ-C30)
Authors: Cielito C Reyes-Gibby; Karen O Anderson; Kelly W Merriman; Knox H Todd; Sanjay S Shete; Ehab Y Hanna Journal: J Pain Date: 2014-07-17 Impact factor: 5.820
Authors: Joel B Epstein; Jennifer L Beaumont; Clement K Gwede; Barbara Murphy; Adam S Garden; Ruby Meredith; Quynh-Thu Le; David Brizel; John Isitt; David Cella Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Johan Haumann; Sander M J van Kuijk; José W Geurts; Frank J P Hoebers; Bernd Kremer; Elbert A Joosten; Marieke H J van den Beuken-van Everdingen Journal: Pain Pract Date: 2017-08-28 Impact factor: 3.183
Authors: K Bjordal; A de Graeff; P M Fayers; E Hammerlid; C van Pottelsberghe; D Curran; M Ahlner-Elmqvist; E J Maher; J W Meyza; A Brédart; A L Söderholm; J J Arraras; J S Feine; H Abendstein; R P Morton; T Pignon; P Huguenin; A Bottomly; S Kaasa Journal: Eur J Cancer Date: 2000-09 Impact factor: 9.162
Authors: Huaising C Ko; Mandira N Mehra; Adam R Burr; Aaron M Wieland; Randal J Kimple; Gregory K Hartig; Paul M Harari; Matthew E Witek Journal: J Pain Manag Date: 2020
Authors: Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Elizabeth A Repasky; Anurag K Singh Journal: Oral Oncol Date: 2020-06-16 Impact factor: 5.337
Authors: Sondos Zayed; Cindy Lin; R Gabriel Boldt; Jinka Sathya; Varagur Venkatesan; Nancy Read; Lucas C Mendez; Dwight E Moulin; David A Palma Journal: Adv Radiat Oncol Date: 2020-10-26
Authors: Malcolm D Mattes; Gita Suneja; Bruce G Haffty; Cristiane Takita; Matthew S Katz; Nitin Ohri; Curtiland Deville; Malika L Siker; Henry S Park Journal: Adv Radiat Oncol Date: 2021-09-10